A correction – as long as it is not too severe – might not be a bad thing for the sector.
This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.
Medtechs rushed for the markets last year, but had an uneasy time once there.
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.